Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix (Nasdaq: NBTX) reported its share capital and voting rights as of May 31, 2026, in line with French market regulations.
The company had 50,807,903 shares outstanding, with 54,304,858 theoretical and 54,282,740 exercisable voting rights on Euronext Paris and Nasdaq.
Nanobiotix (NASDAQ:NBTX) reported Q1 2026 operational and financial updates, highlighting clinical, preclinical, and financing progress.
The company completed a €86.1 million follow-on offering, reported encouraging early JNJ-1900 (NBTXR3) Phase 2 NSCLC data, amended the NANORAY-312 Phase 3 protocol, shared new Nanoprimer preclinical results, and held €42.1 million in cash, supporting operations into 2029.
Nanobiotix (NASDAQ:NBTX), a late-clinical stage biotechnology company, has been added to the Euronext Tech Leaders segment and Euronext Tech Leaders Index as of June 2, 2026.
This inclusion highlights its physics-based nanotherapeutic platforms and may enhance visibility with international technology-focused investors.
Nanobiotix (NASDAQ:NBTX) closed its global offering, including full exercise of underwriters’ option, raising approximately $100 million (€86.1 million) in gross proceeds. The deal comprised 2,218,467 ordinary shares (including ADSs and Additional ADSs) and 345,099 pre-funded warrants at a subscription price of €33.60 per share.
According to the company, net proceeds plus existing cash are expected to fund operations into 2029, mainly supporting Nanoprimer and other platforms, JNJ-1900 (NBTXR3) development, and general corporate purposes.
Nanobiotix (NASDAQ:NBTX) announced that underwriters fully exercised their over-allotment option to buy 33,805 additional ADSs at $38.98, bringing total Global Offering gross proceeds to about $100 million (€86.1 million), before fees.
The deal covers 2,218,467 ordinary shares and 345,099 pre-funded warrants. Nanobiotix plans to allocate less than 10% of net proceeds to JNJ-1900 (NBTXR3), 50–60% to Nanoprimer and other platforms, and 30–40% to general corporate purposes, supporting operations into 2029.
Nanobiotix (NASDAQ:NBTX) priced an oversubscribed global follow-on offering of 225,373 ADSs in the U.S. and 1,959,289 ordinary shares plus 345,099 pre-funded warrants in Europe, raising expected gross proceeds of about $98.6 million (€85.0 million), excluding any over-allotment.
The company plans to allocate 50–60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30–40% to general corporate purposes, and expects funding to support operations into 2029.
Nanobiotix (NASDAQ:NBTX, Euronext:NANO) announced that trading of its ordinary shares on Euronext Paris will resume on May 21, 2026 at 3:30 p.m. Paris time.
Trading was halted earlier that day at the company’s request, linked to a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants.
Nanobiotix (NASDAQ:NBTX) requested a temporary halt of trading in its ordinary shares on Euronext Paris starting May 21, 2026, at 9:00 a.m. CEST.
The halt supports allocation confirmations and pricing for a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants, with trading expected to resume around 3:30 p.m. Paris time.
Nanobiotix (NASDAQ:NBTX) launched an approximately €75 million ($87 million) global follow-on offering of ADSs, ordinary shares and pre-funded warrants, subject to market conditions. The deal combines a U.S. public ADS offering with an international offering for qualified investors.
Pricing is expected before U.S. markets open on May 21, 2026, with a 30-day option for underwriters to buy up to 15% additional ADSs. Nanobiotix plans to use less than 10% of net proceeds for JNJ-1900 (NBTXR3), 50–60% for its Nanoprimer and other platforms, and 30–40% for general corporate purposes.
Nanobiotix (NASDAQ:NBTX) reported Part 1 data from the Johnson & Johnson-sponsored randomized Phase 2 CONVERGE trial of nanoradioenhancer JNJ-1900 (NBTXR3) in stage 3 inoperable NSCLC, presented at ESTRO 2026.
Early results in 7 patients showed ORR 85.7%, CRR 57.1%, and DCR 100% with concurrent chemoradiotherapy and durvalumab.